Pi3K inhibitor in relapsed, indolent or aggressive NHL (#482)
Laufzeit: 01.01.2012 - 31.12.2019
imported
Kurzfassung
Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY 80-6946 in
patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
